institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published loading...Updated

ASCO 25: AZ Pitches Upfront Oral SERD Use in Breast Cancer

Summary by Pharmaphorum
AstraZeneca stakes a claim to first-line treatment of HR+ breast cancer with its oral SERD, as Arvinas/Pfizer reveal their second-line data

3 Articles

All
Left
Center
1
Right

The multinational pharmaceutical company AstraZeneca believes that the future of oncological research is to move away from a universal solution for patients and to anticipate resistance to treatment before it takes place, and in this line it has presented two clinical trials at the main congress of the sector. The entry AstraZeneca presents two trials with promising advances in breast and gastric cancer was first published in Digital Process.

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Endpoints News broke the news in on Sunday, June 1, 2025.
Sources are mostly out of (0)

Similar News Topics